Ida Enquist

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone et al. · Journal of Thoracic Oncology · 2021 · 202 citations

Medicine, Oncology, Pharmacology +13

Murine models of acute neuronopathic Gaucher disease

Ida Enquist, Christophe Lo Bianco, Andreas Ooka et al. · Proceedings of the National Academy of Sciences · 2007 · 198 citations

Life Sciences, Genetics, Pathology +17

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

David R. Spigel, Filippo de Marinis, Giuseppe Giaccone et al. · Annals of Oncology · 2019 · 144 citations

Medicine, Oncology, Pharmacology +11

Effective cell and gene therapy in a murine model of Gaucher disease

Ida Enquist, Eva Nilsson, Andreas Ooka et al. · Proceedings of the National Academy of Sciences · 2006 · 134 citations · Full text

Life Sciences, Genetics, Molecular Biology +15